Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The PACAP receptor: a novel target for migraine treatment.

Literature DB >> 20430318

The PACAP receptor: a novel target for migraine treatment.

Henrik W Schytz¹, Jes Olesen, Messoud Ashina.

Abstract

The origin of migraine pain has not yet been clarified, but accumulating data point to neuropeptides present in the perivascular space of cranial vessels as important mediators of nociceptive input during migraine attacks. Pituitary adenylate cyclase-activating polypeptide (PACAP) is present in sensory trigeminal neurons and may modulate nociception at different levels of the nervous system. Human experimental studies have shown that PACAP-38 infusion induces marked dilatation of extracerebral vessels and delayed migraine-like attacks in migraine patients. PACAP selectively activates the PAC(1) receptor, which suggests a possible signaling pathway implicated in migraine pain. This review summarizes the current evidence supporting the involvement of PACAP in migraine pathophysiology and the PAC(1) receptor as a possible novel target for migraine treatment. Copyright 2010 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier Inc. All rights reserved.

Entities: Disease Gene Species

Mesh：

Substances：

Year: 2010 PMID： 20430318 PMCID： PMC5084100 DOI： 10.1016/j.nurt.2010.02.003

Source DB: PubMed Journal: Neurotherapeutics ISSN： 1878-7479 Impact factor: 7.620

61 in total

Review 1. The role of mast cells in migraine pathophysiology.

Authors: Theoharis C Theoharides; Jill Donelan; Kristiana Kandere-Grzybowska; Aphrodite Konstantinidou
Journal: Brain Res Brain Res Rev Date: 2005-07

2. A systematic comparison of intracellular cyclic AMP and calcium signalling highlights complexities in human VPAC/PAC receptor pharmacology.

Authors: Louise Dickson; Ichiro Aramori; James McCulloch; John Sharkey; Keith Finlayson
Journal: Neuropharmacology Date: 2006-08-23 Impact factor: 5.250

3. Brain stem activation in spontaneous human migraine attacks.

Authors: C Weiller; A May; V Limmroth; M Jüptner; H Kaube; R V Schayck; H H Coenen; H C Diener
Journal: Nat Med Date: 1995-07 Impact factor: 53.440

4. Increased plasma histamine levels in migraine patients.

Authors: R V Heatley; J A Denburg; N Bayer; J Bienenstock
Journal: Clin Allergy Date: 1982-03

5. Three bulbospinal pathways from the rostral medulla of the cat: an autoradiographic study of pain modulating systems.

Authors: A I Basbaum; C H Clanton; H L Fields
Journal: J Comp Neurol Date: 1978-03-15 Impact factor: 3.215

6. Messenger molecules and receptor mRNA in the human trigeminal ganglion.

Authors: J Tajti; R Uddman; S Möller; F Sundler; L Edvinsson
Journal: J Auton Nerv Syst Date: 1999-05-28

7. A nitric oxide donor (nitroglycerin) triggers genuine migraine attacks.

Authors: L L Thomsen; C Kruuse; H K Iversen; J Olesen
Journal: Eur J Neurol Date: 1994-09 Impact factor: 6.089

Review 8. Migraine pain, meningeal inflammation, and mast cells.

Authors: Dan Levy
Journal: Curr Pain Headache Rep Date: 2009-06

9. Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine.

Authors: T W Ho; L K Mannix; X Fan; C Assaid; C Furtek; C J Jones; C R Lines; A M Rapoport
Journal: Neurology Date: 2007-10-03 Impact factor: 9.910

10. Passage of pituitary adenylate cyclase activating polypeptide1-27 and pituitary adenylate cyclase activating polypeptide1-38 across the blood-brain barrier.

Authors: W A Banks; A J Kastin; G Komaki; A Arimura
Journal: J Pharmacol Exp Ther Date: 1993-11 Impact factor: 4.030

21 in total

1. PACAP receptor pharmacology and agonist bias: analysis in primary neurons and glia from the trigeminal ganglia and transfected cells.

Authors: C S Walker; T Sundrum; D L Hay
Journal: Br J Pharmacol Date: 2014-03 Impact factor: 8.739

2. Current understanding of photophobia, visual networks and headaches.

Authors: Rodrigo Noseda; David Copenhagen; Rami Burstein
Journal: Cephalalgia Date: 2018-06-25 Impact factor: 6.292

3. Pituitary adenylate cyclase-activating polypeptide (PACAP) potently dilates middle meningeal arteries: implications for migraine.

Authors: Arsalan U Syed; Masayo Koide; Karen M Braas; Victor May; George C Wellman
Journal: J Mol Neurosci Date: 2012-07-06 Impact factor: 3.444

4. Investigation of the Role of Pituitary Adenylate Cyclase-Activating Peptide (PACAP) and Its Type 1 (PAC1) Receptor in Uterine Contractility during Endometritis in Pigs.

Authors: Barbara Jana; Jarosław Całka; Krzysztof Witek
Journal: Int J Mol Sci Date: 2022-05-13 Impact factor: 6.208

Review 10. Vasoactive intestinal peptide/pituitary adenylate cyclase activating polypeptide, and their receptors and cancer.

Authors: Terry W Moody; Bernardo Nuche-Berenguer; Robert T Jensen
Journal: Curr Opin Endocrinol Diabetes Obes Date: 2016-02 Impact factor: 3.243